Abstract
In order to reduce individual cardiovascular risk, many patients require life-long lipid-lowering therapy, often as a drug combination approach. We aimed to describe the usage pattern, effectiveness and tolerability of long-term treatment with lipid-lowering agents, with particular focus on an oral combination of simvastatin (SIM 10, 20, 40 or 80 mg) plus ezetimibe (EZ 10 mg). A prospective, observational study in 512 general practices throughout Germany. From a sample of patients at moderate or high cardiovascular risk who had previously taken part in a half-year study of an SIM/EZ combination, 5485 patients were documented after 1 year of treatment (mean 58 +/- 16 weeks) with regard to lipid parameters, adverse drug reactions (ADRs) and adverse events. At the start of follow-up, 78.6% of patients were still on the SIM/EZ combination. At the end of follow-up, mean low density lipoprotein cholesterol (LDL-C) in patients on the combination versus those on other lipid-lowering therapy was reduced by 29.3 vs. 17.6% compared with baseline, total cholesterol by 23.1 vs. 14.5%, mean high density lipoprotein cholesterol (HDL-C) was increased by 15.9 vs. 13.4%, and mean triglycerides were reduced by 16.1 vs. 7.9%. Individual LDL-C targ...Continue Reading
References
Jun 16, 1993·JAMA : the Journal of the American Medical Association
Mar 26, 1998·The American Journal of Cardiology·P JonesD Hunninghake
Jun 13, 1998·Archives of Internal Medicine·P McBrideR L Brown
Mar 1, 2000·Archives of Internal Medicine·T A PearsonS Kafonek
Jun 22, 2000·The New England Journal of Medicine·J ConcatoR I Horwitz
Nov 1, 2000·Circulation·R M KraussT L Bazzarre
Nov 10, 2000·Lancet·I R Edwards, J K Aronson
May 23, 2001·JAMA : the Journal of the American Medical Association·UNKNOWN Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
Jun 28, 2003·BMJ : British Medical Journal·M R LawA R Rudnicka
Jan 6, 2004·American Journal of Therapeutics·James M McKenney
Jun 3, 2004·Annals of Internal Medicine·Andreas Laupacis, Muhammad Mamdani
Jul 14, 2004·Circulation·Scott M GrundyUNKNOWN American Heart Association
Sep 1, 2004·JAMA : the Journal of the American Medical Association·James A de LemosUNKNOWN Investigators
Oct 8, 2004·European Journal of Epidemiology·Vicki KristmanPierre Côté
Feb 16, 2005·Expert Opinion on Pharmacotherapy·Peter P Toth, Michael H Davidson
May 13, 2005·Mayo Clinic Proceedings·Thomas A PearsonJoanne Palmisano
May 19, 2005·Current Medical Research and Opinion·C BrohetC Allen
Jun 29, 2005·International Journal of Cardiology·Michel FarnierChristopher Allen
Sep 15, 2005·Heart·D TwardellaH Brenner
Nov 17, 2005·JAMA : the Journal of the American Medical Association·Terje R PedersenUNKNOWN Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group
Apr 1, 2006·Current Medical Research and Opinion·Stella S Daskalopoulou, Dimitri P Mikhailidis
Apr 5, 2007·Current Medical Research and Opinion·Steven K HildemannKurt Bestehorn
Jul 31, 2007·Current Medical Research and Opinion·D P MikhailidisA L Catapano
Apr 1, 2008·The New England Journal of Medicine·Cynthia A JackeviciusHarlan M Krumholz
Apr 1, 2008·The New England Journal of Medicine·John J P KasteleinUNKNOWN ENHANCE Investigators
Apr 1, 2008·The New England Journal of Medicine·Jeffrey M DrazenGregory D Curfman
May 7, 2008·Current Medical Research and Opinion·Steven HildemannChristoph Bode
Sep 25, 2008·Medizinische Klinik·Sigmund SilberUNKNOWN DETECT-Studiengruppe
Dec 23, 2008·Medizinische Klinik·Marc-Alexander OhlowBernward Lauer
Jan 24, 2009·Medizinische Klinik·Christa ClaesJohann-Matthias Graf von der Schulenburg